HBsAg 양성인 비호즈킨 림프종 환자에서 항암 화학요법 후 간 기능 악화

• Published in: The Korean journal of gastroenterology Vol. 35; no. 1; pp. 64 - 72
• Main Authors: 곽진영, Jin Young Kwag, 정숙향, Sook Hyang Jung, 강윤구, Yoon Koo Kang, 한철주, Chul Ju Han, 김유철, You Cheoul Kim, 이진오, Jhin Oh Lee, 류백렬, Baek Yeol Ryoo, 김봉석, Bong Seog Kim, 홍현주, Hyun Ju Hong, 이영우, Young Woo Lee, 이상원, Sang Won Lee, 조진아, Jin A Cho, 이군희, Gun Hee Lee, 김창민, Chang M
• Format: Journal Article
• Language: Korean
• Published: 대한소화기학회 15.04.2000
• Subjects: Anti-cancer chemotherapy; Hepatitis B; Non-Hodgkin`s lymphoma
• ISSN: 1598-9992

Background/Aims: Immunosuppressive therapy such as anti-cancer chemotherapy is often complicated with reactivation of hepatitis B. We tried to investigate the prevalence of hepatitis B virus (HBV) infection in patients with non-Hodgkin's lymphoma (NHL). Furthermore, we evaluated the frequency of hepatic complications, the clinical outcome, and the risk factors associated with the development of hepatic complications in HBsAg-positive patients treated with chemotherapy for NHL. Methods: One hundred eighty-five patients who were diagnosed as NHL and treated with chemotherapy were retrospectively analyzed. Results: The prevalence of HBV infection was 14.1% of the patients. The frequency of hepatic complications in HBsAg-positive patients receiving chemotherapy for NHL was significantly higher than those of HBsAg-negative patients. (50% vs. 10.1%), and the complete response (CR) rate was significantly lower (42.3% vs. 67.9%). We could not find any significant risk factor associated with the development of hepatic complications in HBsAg-positive NHL patients received chemotherapy. Conclusions: For HBsAg-positive NHL patients receiving chemotherapy, special concern and close follow-up is needed because of high frequency of hepatic complication and low CR rate caused by chemotherapy. (Kor J Gastroenterol 2000;35:64 - 72)